These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15965308)

  • 1. Use of ziprasidone in parkinsonian patients with psychosis.
    Gómez-Esteban JC; Zarranz JJ; Velasco F; Lezcano E; Lachen MC; Rouco I; Barcena J; Boyero S; Ciordia R; Allue I
    Clin Neuropharmacol; 2005; 28(3):111-4. PubMed ID: 15965308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
    Oechsner M; Korchounov A
    Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone and psychosis in Parkinson disease.
    Micheli F; Taubenslag N; Gatto E; Scorticati MC
    Clin Neuropharmacol; 2005; 28(5):254. PubMed ID: 16239772
    [No Abstract]   [Full Text] [Related]  

  • 4. Ziprasidone in the treatment of Parkinson's disease psychosis.
    Shiah IS; Lin CL; Mao WC; Luu SU
    Eur Psychiatry; 2006 Dec; 21(8):578-9. PubMed ID: 16139485
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.
    Pintor L; Valldeoriola F; Baillés E; Martí MJ; Muñiz A; Tolosa E
    Clin Neuropharmacol; 2012; 35(2):61-6. PubMed ID: 22388466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
    Brook S; Lucey JV; Gunn KP
    J Clin Psychiatry; 2000 Dec; 61(12):933-41. PubMed ID: 11206599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
    Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
    Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.
    Barak Y; Mazeh D; Plopski I; Baruch Y
    Am J Geriatr Psychiatry; 2006 Jul; 14(7):629-33. PubMed ID: 16816018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
    Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
    Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
    Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
    J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
    DelBello MP; Versavel M; Ice K; Keller D; Miceli J
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.